Pregabalin in generalized anxiety disorder: A placebo-controlled trial

American Journal of Psychiatry

Volumn 160, Issue 3, 2003, Pages 533-540

  Pande, Atul C ^a   Crockatt, Jerri G ^b   Feltner, Douglas E ^b   Janney, Carol A ^b   Smith, Ward T ^b   Weisler, Richard ^b   Londborg, Peter D ^b   Bielski, Robert J ^b   Zimbroff, Dan L ^b   Davidson, Jonathan R T ^b   Liu Dumaw, Maria ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; ADULT; ANXIETY DISORDER; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; MALE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SLEEP;

ADULT; ANTICONVULSANTS; ANXIETY DISORDERS; DIZZINESS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SLEEP; TREATMENT OUTCOME;

EID: 0037364633     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.3.533     Document Type: Article

References (29)

1. Kessler RC, DuPont RL, Berglund P, Wittchen H-U: Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156:1915-1923
2. Freeman AM III, Westphal JR, Norris GT, Roggero BA, Webb PB, Freeman KL, Rush JA, Hearne EM III, Evoniuk G: Efficacy of on-dansetron in the treatment of generalized anxiety disorder (letter). Depress Anxiety 1997; 5:140-141
3. Lecrubier Y, Puech AJ, Azcona A, Bailey PE, Lataste X: A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 1993; 112:129-133
4. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C, Reines S: A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 1995; 37:462-466
5. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC: A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995; 15:428-434
6. Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW: Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 1999; 46:860-862
7. van Vliet IM, den Boer JA, Westenberg HG, Pian KL: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58:164-168
8. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88:1-11
9. Kinsora JJ Jr, Serpa KA, Snyder BJ, Wiley J, Meltzer LT: Anxiolytic-like effects of pregabalin. Abstracts of the Society for Neuroscience 1999; 25:1319
10. Busch JA, Strand JA, Posvar EL, Bockbrader HN, Radulovic LL: Pregabalin (CI-1008) multiple-dose pharmacokinetics and safety/tolerance in healthy volunteers (abstract). Pharm Sci Suppl 1999; 4:2033
11. Busch JA, Strand JA, Posvar EL, Bockbrader HN, Radulovic LL: Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses (abstract). Epilepsia 1998; 39(suppl 6):58
12. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997; 12:232-241
13. Lipman L, Covi R: Outpatient treatment of neurotic depression: medication and group psychotherapy, in Evaluation of the Psychological Therapies. Edited by Spitzer RL, Klein DL. Baltimore, Johns Hopkins University Press, 1976, pp 181-202
14. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ: Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969; 148:87-98
15. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
16. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
17. Rickels K, Schweizer E, Case WG, Greenblatt DJ: Long-term therapeutic use of benzodiazepines, I: effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47:899-907
18. SAS/STAT User's Guide, version 6, 4th ed, vols 1 and 2. Cary, NC, SAS Institute, 1989
19. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802
20. Neter J, Wasserman W, Kutner MH: Applied Linear Statistical Models. Boston, Irwin, 1990, pp 861-898
21. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms, 4th ed. Washington, DC, US Department of Health and Human Services, Food and Drug Administration, 1996
22. Taylor CP, Vartanian MG: Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models (abstract). Epilepsia 1997; 38(suppl 8):35
23. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Liseau P, Perucca E: Progress report on new antiepileptic drugs: a summary of the forth Eilat conference (EILAT IV). Epilepsy Res 1999; 34:1-11
24. Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL: Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock (abstract). Epilepsia 1997; 38(suppl 8):35
25. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M: Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42:229-236
26. Dooley DJ, Donovan CM, Pugsley TA: Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295:1086-1093
27. Dooley DJ, Mieske CA, Borosky SA: Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280:107-110
28. Maneuf YP, Hughes J, McKnight AT: Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001; 93:191-196
29. 2δ subunit of a calcium channel. J Biol Chem 1996; 271:5768-5776